MGNX MacroGenics Inc.

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Sept. 03, 2020 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in September:

  • Citi 15th Annual BioPharma Virtual Conference. MacroGenics’ management will participate in one-on-one meetings and present in the “Novel Antibodies and Protein Therapeutics in Oncology” panel on September 10, 2020 at 10:45 AM ET.
  • HC Wainwright & Co. 22nd Annual Global Investment Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on September 14, 2020 at 10:00 AM ET.
  • Cantor Virtual Global Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on September 16, 2020 at 8:00 AM ET.
  • Morgan Stanley 18th Annual Global Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and a fireside chat on September 17, 2020 at 2:45 PM ET.

Webcasts of each presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at /events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

CONTACTS:

Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172,
EN
03/09/2020

Underlying

MGNXMacroGenics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MacroGenics Inc.

Free Trial
MGNX MacroGenics In...

Macrogenics Inc: 1 director

A director at Macrogenics Inc bought 100,000 shares at 1.505USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

MGNX MACROGENICS INC.
08/22/25 August 22, 2025 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Reports Second Quarter 2025 Financial Results and Highligh...

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents and marketable securities of $176.5 million as of June 30, 2025; cash runway through first half of 2027 ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing inn...

August 14, 2025 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Appoints Eric Risser as President and Chief Executive Offi...

MacroGenics Appoints Eric Risser as President and Chief Executive Officer ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company’s corporate development...

August 13, 2025 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty P...

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that it has entered into a royalty purchase agreement with Sagard i...

June 10, 2025 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthc...

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed under ...

June 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch